Tumoral drugs as possible blastogenic agents the problem of anti-blastic medication.
The author studies the possible transplacentary carcinogenic drugs used in human therapeutics; the study is of an experimental nature, the pregnant mother rat being injected at the 20-21st days of gestation with double the kg/day dose used in human therapeutics. A total of 1,264 rats (Wistar) were utilized, careful note being made of the possible appearance of tumors throughout the lives of the animals. The products and tumoral percentages, both benign as well as malignant, were as follows: Oncotiotepa (0%); Daunoblastine (3.3%); Vinblastine (9%); Bleomycine (12.8%); 5-Fluoro-Uracil (12.87%); Lyovac (cosmogen) (16.6%); Genoxal (17.14%); and Natulan (37.42%). The benign forms predominated in all the tumors produced, but with some of the drugs the malignant varieties produced were made as 39.3% of the tumors. The location and type of tumors were variable; there being cutaneous, glandular, mammary, hepatic, renal, and tumors of the nervous system; there were also tumors of epithelial, connective and nervous variety.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D002273:Carcinogens; D003520:Cyclophosphamide / Q000009:adverse effects; D003609:Dactinomycin / Q000009:adverse effects; D003630:Daunorubicin / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011344:Procarbazine / Q000009:adverse effects; D051381:Rats; D013852:Thiotepa / Q000009:adverse effects; D014747:Vinblastine / Q000009:adverse effects
D000970:Antineoplastic Agents; D002273:Carcinogens; D001761:Bleomycin; D003609:Dactinomycin; D011344:Procarbazine; D014747:Vinblastine; D003520:Cyclophosphamide; D013852:Thiotepa; D005472:Fluorouracil; D003630:Daunorubicin